Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Risedronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 11/20 | 0.78 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.78 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risedronic Acid SCHEMBL5970387 | 1.00 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4755300 | 1.00 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3953153 | 1.00 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL29738088 | 1.00 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL18377 | 0.99 | FDPS (0.80) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL29380338 | 0.99 | FDPS (0.80) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4643040 | 0.97 | FDPS (0.83) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL5175755 | 0.90 | FDPS (0.80) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL5176322 | 0.90 | FDPS (0.70) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3170751 | 0.90 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008065542-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF RISEDRONATE SODIUM | ORCHID CHEMICALS & PHARMACEUTICALS LTD. (US) | 2008-06-05 | — | — | WO | claimed |
| US-20070117781-A1 | Pharmaceutical formulation with improved stability | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2007-05-24 | — | — | US | claimed |
| EP-1680092-A2 | PHARMACEUTICAL FORMULATION WITH IMPROVED STABILITY | Cipla Ltd. (IN) | 2006-07-19 | — | — | EP | claimed |
| WO-2005030177-A2 | PHARMACEUTICAL FORMULATION WITH IMPROVED STABILITY | CIPLA LIMITED (IN) | 2005-04-07 | — | — | WO | claimed |
| EP-4709350-A1 | INCREASING PERMEATION FOR PRE-GASTRIC ABSORPTION OF ACTIVE PHARMACEUTICAL INGREDIENTS | Catalent U.K. Swindon Zydis Limited (GB) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024231554-A1 | INCREASING PERMEATION FOR PRE-GASTRIC ABSORPTION OF ACTIVE PHARMACEUTICAL INGREDIENTS | CATALENT U.K. SWINDON ZYDIS LIMITED (GB) | 2024-11-14 | — | — | WO | disclosed |
| US-20240374524-A1 | INCREASING PERMEATION FOR PRE-GASTRIC ABSORPTION OF ACTIVE PHARMACEUTICAL INGREDIENTS | CATALENT U.K. SWINDON ZYDIS LIMITED (GB) | 2024-11-14 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2023282283-A1 | COMPOSITION FOR IMPROVING ORAL ENVIRONMENT | 明治ホールディングス株式会社 | 2023-01-12 | — | — | WO | disclosed |
| US-11517603-B2 | Bone remodeling accelerator | HOKURIKU UNIVERSITY (JP) | 2022-12-06 | — | — | US | disclosed |
| US-20200268818-A1 | BONE REMODELING ACCELERATOR | HOKURIKU UNIVERSITY (JP) | 2020-08-27 | — | — | US | disclosed |
| EP-3685836-A1 | BONE REMODELING ACCELERATOR | Hokuriku University (JP) | 2020-07-29 | — | — | EP | disclosed |
| WO-2005107714-A2 | METHOD OF FORMING MICROPARTICLES THAT INCLUDE A BISPHOSPHONATE AND A POLYMER | ALKERMES CONTROLLED THERAPEUTICS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005030177-A2 | PHARMACEUTICAL FORMULATION WITH IMPROVED STABILITY | CIPLA LIMITED (IN) | 2005-04-07 | — | — | WO | disclosed |
| EP-1498411-A1 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1252170-B1 | SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID SODIUM AS THE HEMIPENTAHYDRATE OR MONOHYDRATE | PROCTER & GAMBLE (US) | 2004-08-18 | — | — | EP | disclosed |
| EP-1252170-A2 | SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID SODIUM AS THE HEMIPENTAHYDRATE OR MONOHYDRATE | The Procter & Gamble Company (US) | 2002-10-30 | — | — | EP | disclosed |
| US-6410520-B2 | HEATING IN AQUEOUS SOLUTION | THE PROCTER & GAMBLE COMPANY | 2002-06-25 | — | — | US | disclosed |
| US-20020002282-A1 | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2002-01-03 | — | — | US | disclosed |
| WO-2001056983-A2 | SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID SODIUM AS THE HEMIPENTAHYDRATE OR MONOHYDRATE | THE PROCTER & GAMBLE COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517603-B2 | Bone remodeling accelerator | SOST, COL2A1, CXCL12 | FDPS 2719/4885BTN3A1 1831/4885PDE3A 289/4885 |
| US-20200268818-A1 | BONE REMODELING ACCELERATOR | SOST, COL2A1, CXCL12 | FDPS 2719/4885BTN3A1 1831/4885PDE3A 289/4885 |
| US-20020002282-A1 | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate | PHPT1, PPA1, BPGM | FDPS 136/4885BTN3A1 792/4885PDE3A 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.